keyword
MENU ▼
Read by QxMD icon Read
search

Ceftolozane

keyword
https://www.readbyqxmd.com/read/28735046/ceftolozane-tazobactam-activity-against-drug-resistant-enterobacteriaceae-and-pseudomonas-aeruginosa-causing-healthcare-associated-infections-in-australia-and-new-zealand-report-from-an-antimicrobial-surveillance-program-2013-2015
#1
M A Pfaller, D Shortridge, H S Sader, R K Flamm, M Castaneheira
OBJECTIVES: To evaluate the in vitro activity of ceftolozane-tazobactam and comparator agents tested against isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients in Australia and New Zealand with healthcare-associated infection. METHODS: A total of 1,459 gram-negative organisms (440P. aeruginosa and 1,019 Enterobacteriaceae) were consecutively collected from 11 medical centers located in Australia and New Zealand. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria...
July 19, 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/28705666/in-vitro-activity-of-ceftolozane-tazobactam-against-pseudomonas-aeruginosa-and-enterobacteriaceae-isolates-recovered-from-hospitalized-patients-in-germany
#2
Harald Seifert, Barbara Körber-Irrgang, Michael Kresken
To evaluate the activity of ceftolozane/tazobactam in comparison with other broad-spectrum antimicrobials against Pseudomonas aeruginosa and Enterobacteriaceae, 497 non-duplicate P. aeruginosa and 802 Enterobacteriaceae clinical isolates were consecutively collected during the period from September 2014 to April 2015 from patients in Germany with bloodstream, lower respiratory tract, intraabdominal or urinary tract infections. Antimicrobial susceptibility testing was performed by broth microdilution. Results were interpreted according to EUCAST criteria...
July 10, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28689923/in-vitro-activity-of-ceftolozane-tazobactam-in-combination-with-other-classes-of-antibacterial-agents
#3
Cédric Jacqueline, Karen Howland, Laurent Chesnel
OBJECTIVES: Combination antibiotic therapy has been used successfully to treat some patients with bacterial infections. However, although certain combinations may result in beneficial synergistic activity, others may produce antagonistic effects resulting in poor treatment outcomes. Ceftolozane/tazobactam is an antibacterial agent with potent activity against Pseudomonas aeruginosa and many other Gram-negative pathogens, including extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae...
July 6, 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/28674059/in-vivo-emergence-of-resistance-to-novel-cephalosporin-%C3%AE-lactamase-inhibitor-combinations-through-the-duplication-of-the-amino-acid-d149-from-oxa-2-%C3%AE-lactamase-oxa-539-in-st235-pseudomonas-aeruginosa
#4
Pablo A Fraile-Ribot, Xavier Mulet, Gabriel Cabot, Ester Del Barrio-Tofiño, Carlos Juan, José L Pérez, Antonio Oliver
Resistance development to novel cephalosporin-β-lactamase inhibitor combinations during ceftazidime treatment of a surgical infection by Pseudomonas aeruginosa was investigated. Both, initial (97C2) and final (98G1) isolates, belonged to the high-risk clone ST235 and were resistant to carbapenems (oprD-), fluoroquinolones (GyrA-T83I, ParC-S87L) and aminoglycosides (aacA7/aacA8/aadA6). 98G1 additionally showed resistance to ceftazidime, ceftazidime-avibactam and ceftolozane-tazobactam. Sequencing identified blaOXA-2 in 97C2, but 98G1 contained a 3-bp insertion leading to the duplication of the key residue D149 (designated OXA-539)...
July 3, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28674053/in-vitro-activity-of-ceftolozane-tazobactam-and-other-antimicrobial-agents-against-burkholderia-cepacia-complex-and-burkholderia-gladioli
#5
Dale M Mazer, Carol Young, Linda M Kalikin, Theodore Spilker, John J LiPuma
We tested the activity of ceftolozane-tazobactam and 13 other antimicrobial agents against 221 strains of Burkholderia cepacia complex and Burkholderia gladioli. Most strains (82%) were cultured from persons with cystic fibrosis, and most (85%) were recovered since 2011. The ceftolozane-tazobactam MIC was ≤ 8 μg/ml for 77% of the strains. However, the MIC range was broad (≤0.5 to >64 μg/ml; MIC50/90, 2/32 μg/ml). Significant differences in susceptibility to some antimicrobial agents were observed between species...
July 3, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28610832/comparison-of-antimicrobial-activity-between-ceftolozane-tazobactam-and-ceftazidime-avibactam-against-multidrug-resistant-isolates-of-escherichia-coli-klebsiella-pneumoniae-and-pseudomonas-aeruginosa
#6
Adnan Alatoom, Hashim Elsayed, Karen Lawlor, Laila AbdelWareth, Rania El-Lababidi, Lysettee Cardona, Mohammad Mooty, Maria-Fernanda Bonilla, Ahmad Nusair, Imran Mirza
OBJECTIVE: This study compared the activity of ceftolozane-tazobactam and ceftazidime-avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas aeruginosa, isolated from patients admitted to Cleveland Clinic Abu Dhabi, United Arab Emirates. METHODS: In vitro susceptibility was tested using the Etest strip minimum inhibitory concentration (MIC) method, and PCR was used to characterize the carbapenemase enzymes produced by CRE strains...
June 10, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28575437/successful-treatment-of-post-surgical-osteomyelitis-caused-by-xdr-pseudomonas-aeruginosa-with-ceftolozane-tazobactam-monotherapy
#7
Ivan Gentile, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Riccardo Scotto, Federico De Zottis, Gianfranco Di Renzo, Guglielmo Borgia
No abstract text is available yet for this article.
June 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28532194/cost-effectiveness-of-ceftolozane-tazobactam-plus-metronidazole-compared-with-piperacillin-tazobactam-as-empiric-therapy-for-the-treatment-of-complicated-intra-abdominal-infections-based-on-the-in-vitro-surveillance-of-bacterial-isolates-in-the-uk
#8
Vimalanand Prabhu, Jason Foo, Harblas Ahir, Eric Sarpong, Sanjay Merchant
AIMS: An increase in the prevalence of antimicrobial resistance among gram-negative pathogens has been noted recently. A challenge in empiric treatment of complicated intra-abdominal infection (cIAI) is identifying initial appropriate antibiotic therapy, which is associated with reduced length of stay and mortality compared with inappropriate therapy. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam + metronidazole compared with piperacillin/tazobactam (commonly used in this indication) in the treatment of patients with cIAI in UK hospitals...
June 8, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28520867/activity-of-ceftolozane-tazobactam-against-surveillance-and-problem-enterobacteriaceae-pseudomonas-aeruginosa-and-non-fermenters-from-the-british-isles
#9
David M Livermore, Shazad Mushtaq, Daniele Meunier, Katie L Hopkins, Robert Hill, Rachael Adkin, Aiysha Chaudhry, Rachel Pike, Peter Staves, Neil Woodford
Background: We assessed the activity of ceftolozane/tazobactam against consecutive isolates collected in the BSAC Bacteraemia Surveillance from 2011 to 2015 and against 'problem' isolates sent to the UK national reference laboratory from July 2015, when routine testing began. Methods: Susceptibility testing was by BSAC agar dilution with resistance mechanisms identified by PCR and interpretive reading. Results: Data were reviewed for 6080 BSAC surveillance isolates and 5473 referred organisms...
May 16, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28503325/ceftolozane-tazobactam-for-febrile-uti-due-to-multidrug-resistant-pseudomonas-aeruginosa-in-a-patient-with-neurogenic-bladder
#10
Aurélien Dinh, Benjamin Davido, Ruxandra Calin, Julie Paquereau, Clara Duran, Frédérique Bouchand, Véronique Phé, Emmanuel Chartier-Kastler, Martin Rottman, Jérôme Salomon, Patrick Plésiat, Anaïs Potron
INTRODUCTION: Urinary tract infections (UTI) are a major public health problem among spinal cord injury (SCI) patients. They frequently involve multidrug-resistant (MDR) bacteria. Ceftolozane/tazobactam (C/T) is a novel antibiotic combination approved for complicated intra-abdominal and UTI caused by Gram-positive and Gram-negative organisms, including some MDR strains. Little is known about the use of this agent for complicated febrile UTI occurring among SCI patients with neurogenic bladder due to MDR Pseudomonas aeruginosa (PSA)...
2017: Spinal Cord Series and Cases
https://www.readbyqxmd.com/read/28495526/multidrug-resistant-pseudomonas-aeruginosa-skin-and-soft-tissue-infection-successfully-treated-with-ceftolozane-tazobactam
#11
Nadia Castaldo, Filippo Givone, Maddalena Peghin, Elda Righi, Assunta Sartor, Matteo Bassetti
Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor combination antibiotic approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal and urinary tract infections due to Gram-negative bacteria, particularly extended-spectrum β-lactamase-producing Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas aeruginosa strains. Here we report a case of MDR P. aeruginosa skin and soft-tissue infection successfully treated with C/T.
June 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/28483953/ceftolozane-tazobactam-activity-against-pseudomonas-aeruginosa-clinical-isolates-from-u-s-hospitals-report-from-the-pacts-antimicrobial-surveillance-program-2012-to-2015
#12
Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
The activity of ceftolozane-tazobactam was compared to the activities of 7 antimicrobials against 3,851 Pseudomonas aeruginosa isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-tazobactam and comparator susceptibilities were determined using the CLSI broth microdilution method at a central monitoring laboratory. For ceftolozane-tazobactam, 97.0% of the isolates were susceptible. Susceptibilities of the other antibacterials tested were: amikacin, 96...
July 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28464828/analysis-of-patients-with-diabetes-and-complicated-intra-abdominal-infection-or-complicated-urinary-tract-infection-in-phase-3-trials-of-ceftolozane-tazobactam
#13
Myra W Popejoy, Jianmin Long, Jennifer A Huntington
BACKGROUND: Diabetes mellitus and hyperglycemia are associated with increased susceptibility to bacterial infections and poor treatment outcomes. This post hoc evaluation of the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) aimed to evaluate baseline characteristics, efficacy, and safety in patients with and without diabetes treated with ceftolozane/tazobactam and comparators. Ceftolozane/tazobactam is an antibacterial with potent activity against Gram-negative pathogens and is approved for the treatment of cIAI (with metronidazole) and cUTI (including pyelonephritis)...
May 2, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28454524/cost-effectiveness-of-ceftolozane-tazobactam-compared-with-piperacillin-tazobactam-as-empiric-therapy-based-on-the-in-vitro-surveillance-of-bacterial-isolates-in-the-united-states-for-the-treatment-of-complicated-urinary-tract-infections
#14
Teresa L Kauf, Vimalanand S Prabhu, Goran Medic, Rebekah H Borse, Benjamin Miller, Jennifer Gaultney, Shuvayu S Sen, Anirban Basu
BACKGROUND: A challenge in the empiric treatment of complicated urinary tract infection (cUTI) is identifying the initial appropriate antibiotic therapy (IAAT), which is associated with reduced length of stay and mortality compared with initial inappropriate antibiotic therapy (IIAT). We evaluated the cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam (one of the standard of care antibiotics), for the treatment of hospitalized patients with cUTI. METHODS: A decision-analytic Monte Carlo simulation model was developed to compare the costs and effectiveness of empiric treatment with either ceftolozane/tazobactam or piperacillin/tazobactam in hospitalized adult patients with cUTI infected with Gram-negative pathogens in the US...
April 28, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28439137/compatibility-of-ceftazidime-avibactam-ceftolozane-tazobactam-and-piperacillin-tazobactam-with-vancomycin-in-dextrose-5-in-water
#15
Kevin Meyer, Maressa Santarossa, Larry H Danziger, Eric Wenzler
Objectives: The compatibility of vancomycin with existing and novel β-lactam/β-lactamase inhibitors at clinically relevant concentrations in 5% dextrose in water has not been fully explored to date. Methods: Vancomycin concentrations tested ranged from 5 to 20 mg/mL. Ceftazidime-avibactam was tested at 8, 20, and 40 mg/mL, ceftolozane-tazobactam at 15 mg/mL, and piperacillin-tazobactam at 28 mg/mL. Compatibility of drug admixtures were tested via both simulated and actual y-site infusion. For the simulated y-site compatibility assessment, 1:1 mixtures of each respective drug were analyzed over 24 hours...
March 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/28386491/multidrug-resistant-pseudomonas-mycotic-pseudoaneurysm-following-cardiac-transplant-bridged-by-ventricular-assistant-device
#16
C Aye, M Williams, R Horvath
Mycotic pseudoaneurysm of aorta following cardiac surgery is rare but is highly fatal if it is unrecognized and untreated. Here, we report a case of a 45-year-old male patient who presented with rapidly progressive multiple pseudoaneurysms of the ascending aorta infected with multidrug resistant (MDR) Pseudomonas aeruginosa at 5 weeks after cardiac transplantation, on a background of prior bridging therapy with left ventricular assistant device (LVAD). The patient was successfully treated with the newer cephalosporin, Ceftolozane/Tazobactam, in combination with surgery...
2017: Case Reports in Infectious Diseases
https://www.readbyqxmd.com/read/28369471/activity-of-cefiderocol-s-649266-against-carbapenem-resistant-gram-negative-bacteria-collected-from-inpatients-in-greek-hospitals
#17
Matthew E Falagas, Tilemachos Skalidis, Konstantinos Z Vardakas, Nicholas J Legakis
Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases. Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline...
June 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28363945/successful-treatment-of-multidrug-resistant-pseudomonas-aeruginosa-pubic-symphysis-osteomyelitis-with-ceftolozane-tazobactam
#18
Kari E Kurtzhalts, Kari A Mergenhagen, Akshay Manohar, Charles S Berenson
New antibiotic options are needed for the treatment of multidrug-resistant (MDR) Pseudomonas infections. We present a case of a man aged 64 years with a bladder fistula due to radiation, ultimately causing osteomyelitis of the pubic symphysis. Repeated antibiotic courses, without correcting the fistula, resulted in infection with MDR Pseudomonas aeruginosa. He was successfully treated for his osteomyelitis through cystectomy, aggressive debridement and a prolonged course of antimicrobials directed at the MDR Pseudomonas isolate...
March 31, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28362938/the-use-of-noncarbapenem-%C3%AE-lactams-for-the-treatment-of-extended-spectrum-%C3%AE-lactamase-infections
#19
Pranita D Tamma, Jesus Rodriguez-Bano
The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae...
April 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28361526/ceftolozane-tazobactam-for-the-treatment-of-ventilator-associated-infections-by-colistin-resistant-pseudomonas-aeruginosa
#20
F Álvarez Lerma, R Muñoz Bermudez, S Grau, M P Gracia Arnillas, L Sorli, L Recasens, M Mico García
The use of colistin for the treatment of multiresistant bacteria has led to the emergence of colistin-resistant strains of Gram-negative bacilli. Treatment of infections caused by these pan-drug-resistant bacteria is difficult owing to the paucity of effective antibiotics. We report two cases of ventilator-associated respiratory infection caused by pan-drug-resistant, colistin-resistant Pseudomonas aeruginosa that were successfully treated with ceftolozane-tazobactam.
March 29, 2017: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
keyword
keyword
23428
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"